Medical cannabis has a plausible biological connection to irritable bowel syndrome, but a convincing mechanism is not the same as an effective treatment. Small human studies show that cannabinoids can influence bowel movement. They do not establish that prescribed cannabis reliably improves abdominal pain, bloating and everyday functioning over the long term. For someone living with persistent symptoms, the useful question is what has actually been tested, and what remains uncertain.
Evidence checked: 1 October 2026. This educational article is not an individual treatment recommendation. Decisions about prescribed cannabinoids require a qualified clinician.
What IBS involves
IBS is a disorder of gut–brain interaction. Pain, altered bowel habits and sensitivity to intestinal sensations can occur without the pattern of tissue inflammation seen in inflammatory bowel disease. IBS with diarrhoea, IBS with constipation and mixed IBS are different clinical patterns. A treatment that slows bowel movement might be relevant to one pattern while being unhelpful for another. The gut–brain description does not mean symptoms are imaginary. It recognises communication between the digestive tract and nervous system. Bradford Teaching Hospitals explains this distinction.
IBS must also be distinguished from coeliac disease, Crohn’s disease, ulcerative colitis and other causes of bowel symptoms. Feeling better after taking a substance does not confirm the diagnosis. Equally, symptoms persisting despite treatment should prompt reassessment rather than an assumption that progressively stronger cannabis is needed.
Why cannabinoids interest researchers
Cannabinoid receptors participate in the regulation of intestinal activity. THC, the main intoxicating cannabinoid, acts on this signalling system; dronabinol is a pharmaceutical form of THC used in research. CBD is a different compound with different pharmacology. Findings from one cannot simply be transferred to the other.
In a 2011 randomised study involving 75 people with IBS, a single dose of dronabinol reduced some measurements of fasting colonic motility, particularly in participants with diarrhoea or alternating bowel habits. It did not change the measured sensation or tone. This is evidence of a physiological effect, not proof of durable relief from the full IBS symptom pattern.
A 2012 study of 36 people with diarrhoea-predominant IBS tested dronabinol over two days. It did not detect an overall treatment effect on gastric, small-bowel or colonic transit. The short duration, small sample and physiological endpoints limit what can be concluded about ordinary clinical use.
What these studies can and cannot tell us
Motility describes movement and contractions; transit describes how material travels through the gut. Neither is interchangeable with a patient’s experience of pain, urgency or quality of life. A medicine may alter one laboratory measure without making meals, travel or work easier. Conversely, someone might report less distress while their bowel pattern remains unchanged.
The evidence needed for a confident IBS recommendation would include adequately sized controlled trials, clearly defined IBS subtypes, standardised products, meaningful symptom outcomes and follow-up long enough to assess continued benefit and adverse effects. The trials above do not provide that package. They justify further investigation, but they cannot identify a “best IBS strain” or establish CBD oil as an effective IBS medicine.
THC, CBD and the problem of symptom overlap
When a person says cannabis helps their IBS, several different changes may be involved: less abdominal discomfort, better sleep, reduced anxiety about symptoms, or a change in bowel frequency. These are worth recording separately. Improvement in sleep could be valuable, but should not be reported as evidence that the underlying bowel disorder has been corrected.
CBD should not be assumed to be a gentler version of a proven IBS treatment. It has no established IBS-specific benefit from the studies discussed here. It can also cause diarrhoea and interact with medicines. THC-containing products can cause dizziness, sleepiness and unwanted mental effects. Cannabis-associated recurrent severe vomiting is another reason to consider the treatment itself when gastrointestinal symptoms worsen. These risks are described in the NCCIH review of cannabis and cannabinoids.
Where established IBS care fits
NICE guidance for IBS supports an individual approach involving diet, activity and symptom-directed medicines. Options include antispasmodics, treatment for constipation or diarrhoea, and selected low-dose antidepressants for persistent symptoms. A low-FODMAP or other exclusion diet should be guided by someone with appropriate dietary expertise. Psychological approaches, including CBT and gut-directed hypnotherapy, may be considered for refractory symptoms.
These approaches address different aspects of IBS and need not imply that the illness has a single cause. Reviewing what was tried, for how long and with what result is more informative than simply recording that “standard treatment failed”. A medicine stopped because of intolerable adverse effects is a different situation from one never taken at a therapeutic regimen.
How to make a specialist discussion useful
For any proposed treatment trial, agree what success would mean before starting. A short diary can separate abdominal pain, stool consistency, urgency, sleep and activities missed. It should also record adverse effects and changes in other treatments. This makes a follow-up appointment more informative than recalling the best or worst day.
- Confirm the diagnosis and predominant bowel pattern.
- Ask which symptom the proposed medicine is intended to improve.
- Ask what evidence applies to that exact product and that symptom.
- Agree a review date and a plan if benefit is small or adverse effects outweigh it.
- Discuss all prescription medicines, supplements and existing cannabis use.
When symptoms need further assessment
Rectal bleeding, bloody diarrhoea, unexplained substantial weight loss, a hard abdominal swelling, or symptoms suggesting anaemia should not be attributed automatically to IBS. The NHS advises urgent medical assessment for these warning signs. Recurrent severe vomiting or inability to keep fluids down also needs prompt assessment.
The most defensible position is that cannabinoids are an area of investigation for IBS, with limited clinical evidence. A person’s report of relief deserves attention, while a treatment recommendation still needs to account for diagnosis, measurable benefit and harm.
Sources and further reading
- Wong and colleagues, 2011: dronabinol and colonic motility.
- Wong and colleagues, 2012: dronabinol and intestinal transit.
- NICE CG61: IBS assessment and management.
- NHS: IBS symptoms and warning signs.